Cargando…

Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants

Tuberculosis vaccine development is hindered by the lack of validated immune correlates of protection. Exploring immune correlates of risk of disease and/or infection in prospective samples can inform this field. We investigate whether previously identified immune correlates of risk of TB disease al...

Descripción completa

Detalles Bibliográficos
Autores principales:	Satti, Iman, Wittenberg, Rachel E., Li, Shuailin, Harris, Stephanie A., Tanner, Rachel, Cizmeci, Deniz, Jacobs, Ashley, Williams, Nicola, Mulenga, Humphrey, Fletcher, Helen A., Scriba, Thomas J., Tameris, Michele, Hatherill, Mark, McShane, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632577/ https://www.ncbi.nlm.nih.gov/pubmed/36329009 http://dx.doi.org/10.1038/s41467-022-34061-7

Ejemplares similares

Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response
por: Matsumiya, Magali, et al.
Publicado: (2014)

Evaluation of a Human BCG Challenge Model to Assess Antimycobacterial Immunity Induced by BCG and a Candidate Tuberculosis Vaccine, MVA85A, Alone and in Combination
por: Harris, Stephanie A., et al.
Publicado: (2014)

Elevated IgG Responses in Infants Are Associated With Reduced Prevalence of Mycobacterium tuberculosis Infection
por: Logan, Erin, et al.
Publicado: (2018)

T-cell activation is an immune correlate of risk in BCG vaccinated infants
por: Fletcher, Helen A., et al.
Publicado: (2016)

Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection
por: Tanner, Rachel, et al.
Publicado: (2020)

Corrigendum: T-cell activation is an immune correlate of risk in BCG vaccinated infants
por: Fletcher, Helen A., et al.
Publicado: (2016)

Induction of Functional Specific Antibodies, IgG-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination
por: Bitencourt, Julia, et al.
Publicado: (2022)

Gene Expression and Cytokine Profile Correlate With Mycobacterial Growth in a Human BCG Challenge Model
por: Matsumiya, Magali, et al.
Publicado: (2015)

The Humoral Immune Response to BCG Vaccination
por: Tanner, Rachel, et al.
Publicado: (2019)

Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected Children
por: Luabeya, Kany Kany A., et al.
Publicado: (2015)

Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A
por: Harris, Stephanie A., et al.
Publicado: (2014)

Evaluation of Xpert(®) MTB/RIF Assay in Induced Sputum and Gastric Lavage Samples from Young Children with Suspected Tuberculosis from the MVA85A TB Vaccine Trial
por: Bunyasi, Erick Wekesa, et al.
Publicado: (2015)

The Role of Clinical Symptoms in the Diagnosis of Intrathoracic Tuberculosis in Young Children
por: Mulenga, Humphrey, et al.
Publicado: (2015)

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial
por: Tameris, Michele D, et al.
Publicado: (2013)

Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG
por: Tameris, Michele, et al.
Publicado: (2013)

Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial
por: Nemes, Elisa, et al.
Publicado: (2018)

Cytomegalovirus infection is a risk factor for tuberculosis disease in infants
por: Müller, Julius, et al.
Publicado: (2019)

Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines
por: Harris, Stephanie A., et al.
Publicado: (2018)

Editorial Commentary: Understanding BCG Is the Key to Improving It
por: McShane, Helen
Publicado: (2014)

A Human Challenge Model for Mycobacterium tuberculosis Using Mycobacterium bovis Bacille Calmette-Guérin
por: Minassian, Angela M., et al.
Publicado: (2012)

Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical study
por: Wilkie, Morven, et al.
Publicado: (2022)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery()
por: Meyer, Joel, et al.
Publicado: (2013)

Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination
por: Bunyasi, E. W., et al.
Publicado: (2017)

The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells
por: Tanner, Rachel, et al.
Publicado: (2021)

Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis()
por: Poyntz, Hazel C., et al.
Publicado: (2014)

A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates
por: Tanner, Rachel, et al.
Publicado: (2021)

Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A
por: Tanner, Rachel, et al.
Publicado: (2014)

Comparison of haematology and biochemistry parameters in healthy South African infants with laboratory reference intervals
por: Schmidt, B.‐M., et al.
Publicado: (2017)

Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2009)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2011)

High-dose Mycobacterium tuberculosis aerosol challenge cannot overcome BCG-induced protection in Chinese origin cynomolgus macaques; implications of natural resistance for vaccine evaluation
por: Sibley, Laura, et al.
Publicado: (2021)

The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses
por: Tameris, Michele, et al.
Publicado: (2014)

Systematic review of diagnostic and prognostic host blood transcriptomic signatures of tuberculosis disease in people living with HIV
por: Mendelsohn, Simon C, et al.
Publicado: (2023)

Prevalence of latent TB infection and TB disease among adolescents in high TB burden countries in Africa: a systematic review protocol
por: Bunyasi, Erick Wekesa, et al.
Publicado: (2017)

Regional changes in tuberculosis disease burden among adolescents in South Africa (2005–2015)
por: Bunyasi, Erick Wekesa, et al.
Publicado: (2020)

Prevention of Infection with Mycobacterium tuberculosis by H4:IC31® Vaccination or BCG Revaccination in Adolescents
por: Nemes, Elisa, et al.
Publicado: (2018)

A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis
por: Zelmer, Andrea, et al.
Publicado: (2016)

Clinical predictors of pulmonary tuberculosis among South African adults with HIV
por: Mendelsohn, Simon C., et al.
Publicado: (2022)

Immune Profiling Enables Stratification of Patients With Active Tuberculosis Disease or Mycobacterium tuberculosis Infection
por: Duffy, Darragh, et al.
Publicado: (2020)

Using Data from Macaques To Predict Gamma Interferon Responses after Mycobacterium bovis BCG Vaccination in Humans: a Proof-of-Concept Study of Immunostimulation/Immunodynamic Modeling Methods
por: Rhodes, Sophie J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nobqhe1l15hnktfsbkv7q5da8i